Carlsmed (NASDAQ:CARL) Stock Price Target Raised at Truist Financial

Posted by Brenda Bartman on Nov 11th, 2026

Carlsmed (NASDAQ:CARL – Get Free Report) had its price objective increased by investment analysts at Truist Financial from $20.00 to $23.00 in a report issued on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial‘s price target would indicate a potential upside of 56.36% from the company’s current price.

A number of other analysts also recently commented on CARL. Needham & Company LLC boosted their price objective on shares of Carlsmed from $17.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday. Wall Street Zen upgraded shares of Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Carlsmed in a report on Wednesday, November 4th. Finally, BTIG Research lifted their price target on shares of Carlsmed from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $22.00.

Check Out Our Latest Research Report on Carlsmed

Carlsmed Price Performance

Carlsmed stock opened at $14.71 on Wednesday. The company has a market cap of $401.58 million, a P/E ratio of -10.29 and a beta of 1.97. Carlsmed has a one year low of $8.50 and a one year high of $17.23. The business has a fifty day moving average of $14.87 and a two-hundred day moving average of $12.52. The company has a debt-to-equity ratio of 0.18, a quick ratio of 8.66 and a current ratio of 8.84.

Carlsmed (NASDAQ:CARL – Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.08. The business had revenue of $21.55 million for the quarter. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. As a group, analysts predict that Carlsmed will post -1.50 earnings per share for the current fiscal year.

Institutional Trading of Carlsmed

Several large investors have recently bought and sold shares of CARL. Jupiter Topco LLC purchased a new position in shares of Carlsmed in the second quarter valued at $12,992,000. Parkman Healthcare Partners LLC acquired a new position in shares of Carlsmed during the 2nd quarter worth $6,200,000. BlackRock Inc. acquired a new position in shares of Carlsmed during the 2nd quarter worth $5,528,000. KCM Capital Inc purchased a new stake in shares of Carlsmed in the 1st quarter worth about $1,810,000. Finally, Russell Investments Group Ltd. boosted its position in shares of Carlsmed by 85.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 257,805 shares of the company’s stock worth $3,627,000 after buying an additional 118,663 shares in the last quarter.

Carlsmed News Roundup

Here are the key news stories impacting Carlsmed this week:

Positive Sentiment: Third-quarter revenue rose 65% year over year to $21.6 million, and Carlsmed raised its 2026 revenue guidance to $78 million–$80 million. Its loss of $0.34 per share was narrower than the $0.42 consensus estimate. Carlsmed third-quarter results and guidance
Positive Sentiment: BTIG Research raised its price target from $24 to $26 and maintained a Buy rating; Needham & Company raised its target from $17 to $22 and also gave the stock a Buy rating. BTIG Research recommendations Needham recommendations
Positive Sentiment: Management cited new DRG-related tailwinds and fourth-quarter product launches as factors supporting its revenue outlook. Carlsmed outlook and product launches
Negative Sentiment: Despite the earnings beat, Carlsmed continues to report quarterly losses and negative net margins, so continued growth and progress toward profitability remain important risks for investors. Carlsmed third-quarter results

About Carlsmed

(Get Free Report)

Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. The company combines patient-specific planning, advanced imaging, software and additive manufacturing to develop implants designed to address the anatomical needs of individual patients. Its products include the aprevo® patient-specific interbody implant system, which is designed for use in spinal fusion procedures. Carlsmed’s technology is intended to support surgeons in planning procedures and selecting or creating implants that may help restore spinal alignment and improve surgical precision.